Standard

Expanding Horizons of CRISPR/Cas Technology : Clinical Advancements, Therapeutic Applications, and Challenges in Gene Therapy. / Bairqdar, Ahmad; Karitskaya, Polina E.; Stepanov, Grigory A.

в: International Journal of Molecular Sciences, Том 25, № 24, 13321, 12.12.2024.

Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование

Harvard

Bairqdar, A, Karitskaya, PE & Stepanov, GA 2024, 'Expanding Horizons of CRISPR/Cas Technology: Clinical Advancements, Therapeutic Applications, and Challenges in Gene Therapy', International Journal of Molecular Sciences, Том. 25, № 24, 13321. https://doi.org/10.3390/ijms252413321

APA

Bairqdar, A., Karitskaya, P. E., & Stepanov, G. A. (2024). Expanding Horizons of CRISPR/Cas Technology: Clinical Advancements, Therapeutic Applications, and Challenges in Gene Therapy. International Journal of Molecular Sciences, 25(24), [13321]. https://doi.org/10.3390/ijms252413321

Vancouver

Bairqdar A, Karitskaya PE, Stepanov GA. Expanding Horizons of CRISPR/Cas Technology: Clinical Advancements, Therapeutic Applications, and Challenges in Gene Therapy. International Journal of Molecular Sciences. 2024 дек. 12;25(24):13321. doi: 10.3390/ijms252413321

Author

Bairqdar, Ahmad ; Karitskaya, Polina E. ; Stepanov, Grigory A. / Expanding Horizons of CRISPR/Cas Technology : Clinical Advancements, Therapeutic Applications, and Challenges in Gene Therapy. в: International Journal of Molecular Sciences. 2024 ; Том 25, № 24.

BibTeX

@article{d197c971a5ce46079044a0cdde1f6692,
title = "Expanding Horizons of CRISPR/Cas Technology: Clinical Advancements, Therapeutic Applications, and Challenges in Gene Therapy",
abstract = "CRISPR–Cas technology has transformed the field of gene editing, opening new possibilities for treatment of various genetic disorders. Recent years have seen a surge in clinical trials using CRISPR–Cas-based therapies. This review examines the current landscape of CRISPR–Cas implementation in clinical trials, with data from key registries, including the Australian New Zealand Clinical Trials Registry, the Chinese Clinical Trial Register, and ClinicalTrials.gov. Emphasis is placed on the mechanism of action of tested therapies, the delivery method, and the most recent findings of each clinical trial.",
keywords = "CRISPR–Cas, gene therapy, genome editing, xenotransplantation, CRISPR–Cas, gene therapy, genome editing, xenotransplantation",
author = "Ahmad Bairqdar and Karitskaya, {Polina E.} and Stepanov, {Grigory A.}",
note = "Сведения о финансировании: Ministry of Education and Science of the Russian Federation 075-15-2021-1085",
year = "2024",
month = dec,
day = "12",
doi = "10.3390/ijms252413321",
language = "English",
volume = "25",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "24",

}

RIS

TY - JOUR

T1 - Expanding Horizons of CRISPR/Cas Technology

T2 - Clinical Advancements, Therapeutic Applications, and Challenges in Gene Therapy

AU - Bairqdar, Ahmad

AU - Karitskaya, Polina E.

AU - Stepanov, Grigory A.

N1 - Сведения о финансировании: Ministry of Education and Science of the Russian Federation 075-15-2021-1085

PY - 2024/12/12

Y1 - 2024/12/12

N2 - CRISPR–Cas technology has transformed the field of gene editing, opening new possibilities for treatment of various genetic disorders. Recent years have seen a surge in clinical trials using CRISPR–Cas-based therapies. This review examines the current landscape of CRISPR–Cas implementation in clinical trials, with data from key registries, including the Australian New Zealand Clinical Trials Registry, the Chinese Clinical Trial Register, and ClinicalTrials.gov. Emphasis is placed on the mechanism of action of tested therapies, the delivery method, and the most recent findings of each clinical trial.

AB - CRISPR–Cas technology has transformed the field of gene editing, opening new possibilities for treatment of various genetic disorders. Recent years have seen a surge in clinical trials using CRISPR–Cas-based therapies. This review examines the current landscape of CRISPR–Cas implementation in clinical trials, with data from key registries, including the Australian New Zealand Clinical Trials Registry, the Chinese Clinical Trial Register, and ClinicalTrials.gov. Emphasis is placed on the mechanism of action of tested therapies, the delivery method, and the most recent findings of each clinical trial.

KW - CRISPR–Cas

KW - gene therapy

KW - genome editing

KW - xenotransplantation

KW - CRISPR–Cas

KW - gene therapy

KW - genome editing

KW - xenotransplantation

UR - https://www.mendeley.com/catalogue/88105690-6d52-3ddd-8634-2b9cca2f0b55/

UR - https://www.scopus.com/record/display.uri?eid=2-s2.0-85213212531&origin=inward&txGid=a3b6b1fd377be507ad1c01cda29b9323

U2 - 10.3390/ijms252413321

DO - 10.3390/ijms252413321

M3 - Article

C2 - 39769084

VL - 25

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 24

M1 - 13321

ER -

ID: 61420984